BR112019005069A2 - compostos inovadores - Google Patents

compostos inovadores

Info

Publication number
BR112019005069A2
BR112019005069A2 BR112019005069A BR112019005069A BR112019005069A2 BR 112019005069 A2 BR112019005069 A2 BR 112019005069A2 BR 112019005069 A BR112019005069 A BR 112019005069A BR 112019005069 A BR112019005069 A BR 112019005069A BR 112019005069 A2 BR112019005069 A2 BR 112019005069A2
Authority
BR
Brazil
Prior art keywords
skin color
innovative compounds
compounds
innovative
natural
Prior art date
Application number
BR112019005069A
Other languages
English (en)
Inventor
Jackson Eileen
Heidl Marc
Original Assignee
Dsm Ip Assets Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets Bv filed Critical Dsm Ip Assets Bv
Publication of BR112019005069A2 publication Critical patent/BR112019005069A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

a presente invenção se refere a compostos inovadores que inibem de modo eficaz a síntese de melanina em melanócitos humanos e são, então, adequados para o tratamento de lentigos senis, para suavizar as irregularidades de cor de pele e/ou para clarear a cor de pele natural.
BR112019005069A 2016-09-15 2017-09-13 compostos inovadores BR112019005069A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16188886 2016-09-15
PCT/EP2017/072952 WO2018050663A1 (en) 2016-09-15 2017-09-13 Novel compounds

Publications (1)

Publication Number Publication Date
BR112019005069A2 true BR112019005069A2 (pt) 2019-06-04

Family

ID=56943360

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019005069A BR112019005069A2 (pt) 2016-09-15 2017-09-13 compostos inovadores

Country Status (7)

Country Link
US (1) US10836791B2 (pt)
EP (1) EP3512867B1 (pt)
JP (1) JP6996042B2 (pt)
KR (1) KR102477100B1 (pt)
CN (1) CN109689676B (pt)
BR (1) BR112019005069A2 (pt)
WO (1) WO2018050663A1 (pt)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU671850B2 (en) * 1992-07-29 1996-09-12 Merrell Dow Pharmaceuticals Inc. Peptide lung surfactants and therapeutic combinations
US6602856B1 (en) * 1995-01-17 2003-08-05 J. Mark Quillan Antagonists of alpha-melanocyte stimulating hormone and methods based thereon
US20030194445A1 (en) 2001-11-12 2003-10-16 Kuhner Carla H. Compositions and methods of use of peptides in combination with biocides and/or germicides
US7863417B2 (en) * 2003-05-08 2011-01-04 Dsm Ip Assets B.V. Tripeptides and derivatives thereof for cosmetic application in order to improve skin structure
FR2870243B1 (fr) 2004-05-11 2010-11-19 Centre Nat Rech Scient Conjugues tripeptidiques agonistes de la msh
KR20080046677A (ko) 2005-09-23 2008-05-27 디에스엠 아이피 어셋츠 비.브이. 오피오이드 수용체 길항제의 용도
JP5568008B2 (ja) * 2007-06-27 2014-08-06 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ペプチドチロシナーゼインヒビターおよびその使用
EP2222325A2 (en) * 2007-11-19 2010-09-01 Universitätsklinikum Münster Compositions for reducing oxidative stress and uses thereof
CN102387772A (zh) * 2008-05-29 2012-03-21 唐纳德·欧文 皮肤美容组合物中的寡聚生物表面活性剂
AU2010237349B2 (en) * 2009-04-17 2014-05-29 Lipotec S.A. Peptides used in the treatment and/or care of the skin and/or hair and their use in cosmetic or pharmaceutical compositions
CN102492018A (zh) * 2010-07-27 2012-06-13 萧乃文 酪氨酸酶多肽抑制剂
CN104072579B (zh) 2014-06-11 2017-01-25 南方医科大学 具有抗菌抗病毒活性的小分子肽及其活性修饰物

Also Published As

Publication number Publication date
EP3512867A1 (en) 2019-07-24
US10836791B2 (en) 2020-11-17
EP3512867B1 (en) 2020-12-16
JP6996042B2 (ja) 2022-01-17
CN109689676B (zh) 2022-10-18
JP2019529376A (ja) 2019-10-17
CN109689676A (zh) 2019-04-26
US20190263858A1 (en) 2019-08-29
WO2018050663A1 (en) 2018-03-22
KR20190049841A (ko) 2019-05-09
KR102477100B1 (ko) 2022-12-13

Similar Documents

Publication Publication Date Title
MX2015011966A (es) Compuestos de resorcinol para uso dermatologico.
CY1122603T1 (el) Γαμμα-δικετονες για τη θεραπευτικη αντιμετωπιση και την προληψη της γηρανσης του δερματος και των ρυτιδων
MX2017015473A (es) Tratamiento contra el cancer por manipulacion de la microflora comensal.
DK3377637T3 (da) Sammensætninger til anvendelse i fremgangsmåder til behandling af sår, lidelser og sygdomme i huden
BR112017015059A2 (pt) inibidor de proteassoma e uso
ZA201902275B (en) Topical dressing composition for the treatment of damaged skin tissue
EP3538119A4 (en) COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES AND MAINTAINING HEALTHY SKIN
MY196718A (en) Composition for skin whitening comprising b-mangostin as effective ingredient
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
PH12019502721A1 (en) Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin
BR112013003846A2 (pt) métodos de tratamento de celulite
BR112016025333A2 (pt) agente, produto e uso
BR112015024703A2 (pt) formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose
MX2015009054A (es) Composicion cosmetica o dermatologica que comprende una merocianina, una fase aceitosa y un monoalcanol c1-c4.
MX2017013819A (es) Metodos para la reduccion de grasa.
BR112018000589A2 (pt) composição de tratamento de cabelo, método para o tratamento de cabelo e utilização de uma composição
EA201391438A1 (ru) Производные сулиндака, применение и получение указанных производных
BR112018006170A2 (pt) método e composição para clareamento de pele usando um extrato de cultura celular de earliella scabrosa
BR112017012938A2 (pt) uso por via oral de uma composição e método para aprimorar a aparência da celulite
BR112019005069A2 (pt) compostos inovadores
BR112018011857A2 (pt) uso de dipeptídeos que contêm prolina
BR112015022265B8 (pt) Composições pigmentadas para tratamento da pele
BR112015022275B8 (pt) Composições pigmentadas para tratamento da pele
WO2014111569A3 (en) Anhydrous cosmetic or dermatological composition comprising a merocyanine and an oily phase
EP3419661A4 (en) METHOD AND COMPOSITION FOR TREATING CANCER OR SKIN INJURY USING A VACCINE

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]